10:11 AM EDT, 04/02/2024 (MT Newswires) -- Autolus Therapeutics ( AUTL ) said Tuesday the European Medicines Agency accepted its marketing authorization application for its lead investigational chimeric antigen receptor T cell therapy called obecabtagene autoleucel, or obe-cel.

The application was based on data from a phase 2 study of obe-cel in relapsed/refractory adult B-cell acute lymphoblastic leukemia, the company said.

Price: 5.64, Change: -0.04, Percent Change: -0.70